MaaT Pharma SA (EPA:MAAT)

Market Cap	67.00M
Revenue (ttm)	3.92M
Net Income (ttm)	-31.13M
Shares Out	16.11M
EPS (ttm)	-2.15
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	102,032
Average Volume	76,508
Open	4.260
Previous Close	4.230
Day's Range	4.160 - 4.400
52-Week Range	3.550 - 9.960
Beta	-0.07
RSI	51.73
Earnings Date	Mar 30, 2026

About MaaT Pharma

MaaT Pharma SA, a late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival. Its products pipeline includes MaaT013, that is in pivotal phase 3 clinical trial for the treatment of acute graft versus host diseases with gastrointestinal involvement; MaaT033, which is in phase 2b clinical trial for the improvement of survival at 12 months for patients with blood cancer receiving allogenic hematopoietic stem cell transplantation; and MaaT03X for the treatment...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 67
• Stock Exchange: Euronext Paris
• Ticker Symbol: MAAT

Financial Performance

In 2024, MaaT Pharma's revenue was 3.22 million, an increase of 44.34% compared to the previous year's 2.23 million. Losses were -28.90 million, 46.6% more than in 2023.